All News
Pfizer and Roivant have joined forces to form yet another Vant. The new entity will initially work to commercialize RVT-3101 for ulcerative colitis.
SQZ Biotechnologies is slashing 60% of its workforce and looking for a new CEO after initiating a strategic prioritization to focus on its cell therapy platform for solid tumors.
PictorLabs emerged from stealth mode Thursday with $18.8 million to advance its AI-powered virtual staining platform that researchers hope will “reimagine the future” of histopathology.
BioSpace sat down with Roche Global Head of Neurodegeneration Rachelle Doody, Ph.D. and Alzheimer’s Drug Discovery Foundation Co-founder Howard Fillit, M.D. to discuss the highlights.
Four months after implementing a restructuring initiative to extend cash flow, X4 Pharmaceuticals is celebrating positive top-line results in WHIM syndrome.
The role of a clinical research nurse can be rewarding, but it’s not without challenges. Find out more about the role of a clinical research nurse and what it takes to become one in our guide.
Shares of Horizon Therapeutics are soaring in premarket trading Wednesday after the rare disease company confirmed it is being courted for a potential acquisition by three pharma giants.
Nimbus reported positive Phase IIb results for NDI-034858 in moderate-to-severe plaque psoriasis, which researchers hope will have the efficacy of JAK inhibitors without the safety issues.
Nectin Therapeutics announced dosing of the first solid tumor patient in a Phase I clinical trial while additional investors jumped in to expand the company’s Series A to just over $25 million.
Full data from the Phase III Clarity AD trial show Eisai and Biogen’s lecanemab has a favorable safety profile in patients with Alzheimer’s disease.
BigHat Biosciences will team up with Merck to design candidates for three drug discovery programs backed by the company’s proprietary AI technology platform.
BMS is terminating a seven-year-old gene therapy collaboration to develop potential treatments for congestive heart failure with uniQure N.V. valued at $1 billion.
With $96 million in Series A financing, Cajal Neuroscience launched Tuesday to develop drug candidates to target neurodegeneration in Alzheimer’s and Parkinson’s diseases.
As the FDA cracks down on accelerated approvals, Genentech, a Roche company, voluntarily withdrew its monoclonal antibody, Tecentriq, for metastatic bladder cancer.
AstraZeneca and Neogene have entered into a definitive acquisition agreement in which AstraZeneca will buy all outstanding equity in the smaller company.
The U.S. Space Force’s Space Launch Delta 30 at Vandenberg Space Force Base has awarded Amentum a $59 million contract
The U.S. Department of Treasury’s Office of Terrorism and Financial intelligence (TFI) has selected Amentum, under its METIS Solutions entity, to provide a full range of
Amentum has been awarded a 5th consecutive environmental services contract to support the Pennsylvania Department of Environmental Protection (PADEP)
Amentum’s Liberty Village team recently received the International Stability Operations Association’s Vanguard Global Achievement Award in recognition of
Amentum has been awarded a $126 million, five-year contract by the U.S. Air Force for the Defense Technical Information Center (DTIC)